Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US12263164B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2023 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Aug 16, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.